Journal
FUTURE ONCOLOGY
Volume 13, Issue 23, Pages 2045-2051Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2017-0167
Keywords
DNA methylation; pancreatic cancer; telomerase; THOR
Categories
Funding
- FCT [PD/BD/105899/2014]
- LPCC-Fundacao PT fellowships
- CNPQ (Brazilian National Council for Science and Technology, Brasilia, DF, Brazil [402621/2016-6]
- Fundação para a Ciência e a Tecnologia [PD/BD/105899/2014] Funding Source: FCT
Ask authors/readers for more resources
Aim: We explore the biomarker potential of the TERT hypermethylated oncologic region (THOR) in pancreatic cancer. Materials & methods: We assessed the methylation status of THOR using the cancer genome atlas data on the cohort of pancreatic cancer (n = 193 patients). Results: THOR was significantly hypermethylated in pancreatic tumor tissue when compared with the normal tissue used as control (p < 0.0001). Also, THOR hypermethylation could distinguish early stage I disease from normal tissue and was associated with worse prognosis. Discussion: We found that THOR is hypermethylated in pancreatic tumor tissue when compared with normal tissue and that THOR methylation correlates with TERT expression in tumor samples. Conclusion: Our preliminary findings support the diagnostic and prognostic values of THOR in pancreatic cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available